JPH11514990A - ２−メルカプトエタノールアミン（２−ｍｅａ）と類縁アミノチオール化合物および３，５−ジイソプロピルサリチル酸銅（▲ｉｉ▼）と類縁化合物の、各種疾患を予防および治療するための使用 - Google Patents

２−メルカプトエタノールアミン（２−ｍｅａ）と類縁アミノチオール化合物および３，５−ジイソプロピルサリチル酸銅（▲ｉｉ▼）と類縁化合物の、各種疾患を予防および治療するための使用

Info

Publication number
JPH11514990A
JPH11514990A JP9513260A JP51326097A JPH11514990A JP H11514990 A JPH11514990 A JP H11514990A JP 9513260 A JP9513260 A JP 9513260A JP 51326097 A JP51326097 A JP 51326097A JP H11514990 A JPH11514990 A JP H11514990A
Authority
JP
Japan
Prior art keywords
mea
cells
composition
patient
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP9513260A
Other languages
English (en)
Japanese (ja)
Inventor
チャチョウア，サミー
Original Assignee
チャチョウア，サミー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by チャチョウア，サミー filed Critical チャチョウア，サミー
Publication of JPH11514990A publication Critical patent/JPH11514990A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP9513260A 1995-09-25 1996-09-25 ２−メルカプトエタノールアミン（２−ｍｅａ）と類縁アミノチオール化合物および３，５−ジイソプロピルサリチル酸銅（▲ｉｉ▼）と類縁化合物の、各種疾患を予防および治療するための使用 Ceased JPH11514990A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US428195P 1995-09-25 1995-09-25
US60/004,281 1995-09-25
PCT/IB1996/001059 WO1997011666A2 (fr) 1995-09-25 1996-09-25 Utilisation de 2-mercaptoethanolamine (2-mea) et de composes aminothiols similaires, en combinaison avec du 3,5-diisopropyl-salicylate de cuivre (ii) et des composes similaires, pour le traitement et la prevention de differentes maladies

Publications (1)

Publication Number Publication Date
JPH11514990A true JPH11514990A (ja) 1999-12-21

Family

ID=21710013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9513260A Ceased JPH11514990A (ja) 1995-09-25 1996-09-25 ２−メルカプトエタノールアミン（２−ｍｅａ）と類縁アミノチオール化合物および３，５−ジイソプロピルサリチル酸銅（▲ｉｉ▼）と類縁化合物の、各種疾患を予防および治療するための使用

Country Status (5)

Country Link
EP (2) EP0858327A2 (fr)
JP (1) JPH11514990A (fr)
AU (2) AU7143196A (fr)
CA (2) CA2233015A1 (fr)
WO (2) WO1997011667A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994409A (en) 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds
US6384259B1 (en) 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
DK1220678T3 (da) * 1999-10-04 2007-07-09 John Carter Farmaceutiske præparater indeholdende kobber, salicylsyre og C-vitamin
US7927612B2 (en) 2000-01-19 2011-04-19 Baofa Yu Combinations and methods for treating neoplasms
US6811788B2 (en) 2000-01-19 2004-11-02 Baofa Yu Combinations and methods for treating neoplasms
US6506413B1 (en) * 2001-04-30 2003-01-14 Joseph C. Ramaekers Compositions for treating animal diseases and syndromes
US7053072B2 (en) 2001-05-11 2006-05-30 Medimmune Oncology, Inc. Methods for the administration of amifostine and related compounds
FR2825923B1 (fr) * 2001-06-15 2006-04-07 Oreal Inhibiteur de no-synthase et utilisations
KR20030077743A (ko) * 2002-03-26 2003-10-04 변현규 In½
US7629333B2 (en) 2002-03-29 2009-12-08 Medimmune, Llc Stable amorphous amifostine compositions and methods for the preparation and use of same
WO2004024129A1 (fr) * 2002-09-10 2004-03-25 Samir Chachoua Therapie induisant une remission
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US9125874B2 (en) 2007-11-30 2015-09-08 The Ramaekers Family Trust Administration of transfer factor for improving reproductive health
CN101138634A (zh) 2006-09-07 2008-03-12 于保法 用于治疗肿瘤的组合物
WO2009070788A1 (fr) 2007-11-30 2009-06-04 The Ramaekers Family Trust Compositions et procédés d'amélioration de la fertilité
WO2010093606A1 (fr) * 2009-02-11 2010-08-19 Martin Heath Bluth Echange réciproque sérum/plasma pour le traitement du cancer
CN107106531A (zh) 2014-11-26 2017-08-29 于保法 微创精准个体化肿瘤内化学诱导免疫治疗方法半抗原增强的化学免疫治疗

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228127A (en) * 1978-10-06 1980-10-14 International Radioimmune Systems, Inc. Kit for detecting human chorionic gonadotropin
US4952607A (en) * 1982-05-27 1990-08-28 International Copper Research Association, Inc. Copper complex for treating cancer
US5057314A (en) * 1988-09-30 1991-10-15 Whitfill Craig E Low molecular weight antiviral factors
US5310653A (en) * 1989-10-24 1994-05-10 Board Of Regents, The University Of Texas System Tumor marker protein and antibodies thereto for cancer risk assessment or diagnosis
US5488042A (en) * 1992-03-13 1996-01-30 Arch Development Corporation Method for protection against genotoxic mutagenesis
DE4236069A1 (de) * 1992-10-26 1994-04-28 Werner Dr Bergmann Arzneimittel, insbesondere für orale Einnahme
WO1994028934A1 (fr) * 1993-06-07 1994-12-22 Center For Special Immunology Traitement adoptif de reconstitution immunitaire pour des patients atteints d'immunodeficiences acquises

Also Published As

Publication number Publication date
EP0853486A2 (fr) 1998-07-22
AU6999096A (en) 1997-04-17
WO1997011667A2 (fr) 1997-04-03
EP0858327A2 (fr) 1998-08-19
AU7143196A (en) 1997-04-17
CA2233015A1 (fr) 1997-04-03
WO1997011667A3 (fr) 1997-06-12
WO1997011666A2 (fr) 1997-04-03
WO1997011666A3 (fr) 1997-06-19
EP0853486A4 (fr) 2001-09-26
CA2233445A1 (fr) 1997-04-03

Similar Documents

Publication Publication Date Title
JPH11514990A (ja) ２−メルカプトエタノールアミン（２−ｍｅａ）と類縁アミノチオール化合物および３，５−ジイソプロピルサリチル酸銅（▲ｉｉ▼）と類縁化合物の、各種疾患を予防および治療するための使用
AU767892B2 (en) New combined preparation for the treatment of neoplasic diseases or of infectious diseases
RU2153332C2 (ru) Способ сенсибилизации раковых клеток к лизису, опосредованному клетками-киллерами
Teixeira et al. Malignant, non-Hodgkin's lymphomas in Trypanosoma cruzi-infected rabbits treated with nitroarenes
Dhuley Therapeutic efficacy of Ashwagandha against experimental aspergillosis in mice
Siveen et al. Augmentation of humoral and cell mediated immune responses by Thujone
KR102004346B1 (ko) 지방 분해능을 갖는 균주를 포함하는 탈모 방지 또는 발모 촉진용 조성물
US6258847B1 (en) Use of 2-mercaptoethanolamine (2-MEA) and related aminothiol compounds and copper(II)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various diseases
KR101790548B1 (ko) 지방 분해능을 갖는 균주를 포함하는 탈모 방지 또는 발모 촉진용 조성물
UA79952C2 (en) MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
RU2269359C2 (ru) Способ профилактики развития онкологических заболеваний или инфекций, вызываемых бактериями, грибами и простейшими, или атеросклероза, или сахарного диабета, или заболеваний, связанных с реакцией гиперчувствительности замедленного типа, или заболеваний, развивающихся вследствие мутации генов соматических клеток (варианты)
US6726913B1 (en) Treatment of dermal tumors, warts, and viral infections of the respiratory tract in humans using heat-killed P. acnes
RU2033157C1 (ru) Средство, обладающее интерферониндуцирующей и иммуномодулирующей (иммуностимулирующей) активностью
CA2251690C (fr) Nouvelles indications pour l&#39;utilisation comme medicaments d&#39;inducteurs para-immunitaires obtenus a partir de poxvirus et parapoxvirus attenues non immunogenes
JPS6212721A (ja) 椎茸霊芝の製造法
EP1220688A1 (fr) Traitement de tumeurs cutanees, verrues et infections virales utilisant du p. acnes tue par la chaleur
CN103710264B (zh) 一种灵芝孢子的破壁辅助添加剂
Dreno Roferon‐A (interferon alpha 2a) combined with tigason (etretinate) for treatment of cutaneous T cell lymphomas
Erciyas Murrembeena (AU)
KR20220113456A (ko) 암의 재발을 예방하기 위한 조성물 및 방법
CN107617101B (zh) 含唑来膦酸和白细胞介素2的药物组合及其应用
WO1988007367A2 (fr) Derives de melatonine pour stress psychogene et anxiete aigue, et medicaments immuno-stimulants
AU2004200804A1 (en) Use of 2-Mercaptoethanolamine (2-mea) and related aminothiol compounds and copper(II)-3,5 di-isopropyl salicylates and related compounds in the prevention and treatment of various disease
RU2207127C1 (ru) Способ лечения экспериментального туберкулеза
JP2001231495A (ja) 好酸球集積抑制作用を有する食品

Legal Events

Date Code Title Description
A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20040330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20040420